文献速递糖尿病

妊娠期糖尿病患者使用糖尿病技术的管理策略

Approach to the Patient Using Diabetes Technology in Pregnancy.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

妊娠期糖尿病增加母婴并发症风险,严格控制血糖可降低风险。本综述评估连续葡萄糖监测(CGM)和混合闭环(HCL)胰岛素泵在妊娠期的应用数据,并指出获取技术和支持系统可能造成医疗差异。

要点

  • 1型糖尿病妊娠中,CGM可改善血糖控制并降低新生儿并发症风险。
  • 国际共识指南推荐妊娠期目标范围内时间(TIR)>70%,范围为63-140 mg/dL。
  • HCL胰岛素泵在1型糖尿病妊娠中改善血糖结局,但结果因系统和目标而异。

核心结论

  • 在1型糖尿病妊娠中,CGM可改善血糖控制并降低新生儿并发症风险,HCL胰岛素泵在随机对照试验中显示改善血糖结局。
  • 在2型糖尿病和妊娠期糖尿病中,回顾性数据提示CGM可改善血糖,但结局和最佳CGM目标的数据有限。

研究设计与样本

  • 本综述旨在呈现和评估当前关于妊娠期使用CGM和HCL胰岛素泵的数据。

主要发现

  • 国际共识指南推荐妊娠期目标范围内时间(TIR)>70%,范围为63-140 mg/dL(3.5-7.8 mmol/L)。
  • 有数据提示1型糖尿病妊娠中更高的TIR可降低胎儿过度生长和子痫前期等并发症风险。
  • 近期随机对照试验显示HCL胰岛素泵在1型糖尿病妊娠中改善血糖结局,但结果因所用系统和可用血糖目标而异。
  • 在2型糖尿病和妊娠期糖尿病中,回顾性数据提示CGM可改善血糖,但关于结局或最佳CGM目标的数据有限。
  • 研究已报告无糖尿病妊娠的血糖指标,可作为2型糖尿病和妊娠期糖尿病进一步结局研究的参考。

关键数值与推荐

  • 国际共识指南推荐妊娠期目标范围内时间(TIR)>70%,范围为63-140 mg/dL(3.5-7.8 mmol/L)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在2型糖尿病和妊娠期糖尿病中,关于结局或最佳CGM目标的数据有限。
  • 获取糖尿病技术和支持使用这些设备所需的医疗保健系统可能是导致医疗差异的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes in pregnancy increases risk for complications for the pregnant patient and neonate. Tight glycemic control to maintain glucose levels as close to nondiabetic ranges as possible can lower risk for these complications. Achieving strict glycemic targets can be challenging, and technologies including continuous glucose monitors (CGMs) and hybrid closed-loop (HCL) insulin pumps have the potential to improve diabetes control and pregnancy outcomes. The aim of this review is to present and appraise the current data about use of these technologies in pregnancy. In pregnancies with type 1 diabetes (T1D), CGM can improve glycemic control and reduce risk for neonatal complications. International consensus guidelines recommend more than 70% time in pregnancy target range (TIR) of 63 to 140 mg/dL (3.5-7.8 mmol/L), and there are data to suggest higher TIR in pregnancies with T1D can reduce risk for neonatal complications including fetal overgrowth and pregnancy complications like preeclampsia. Recent randomized controlled trials have demonstrated improved glycemic outcomes with use of HCL insulin pumps in pregnancy with T1D, though the results vary depending on the system used and available glycemic targets. In pregnancies with type 2 diabetes (T2D) and gestational diabetes mellitus (GDM), retrospective data suggest CGM can improve glycemia but there are limited data about outcomes or optimal CGM targets. Studies have reported glycemic measures for pregnancies without diabetes, which may serve as a guide for further outcomes studies of T2D and GDM. Access to diabetes technology and the necessary health care systems to support use of these devices may be barriers that contribute to health care disparities.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dickens LT, Gonzalez MG. Approach to the Patient Using Diabetes Technology in Pregnancy. J Clin Endocrinol Metab. 2025. PMID: 39775858. doi:10.1210/clinem/dgae914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。